Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 14/20 | 0.75 |
| ▸ | MAOA known ✓ | P21397 | 12/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 13/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.75 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.75 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL5070770 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL40650 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL5075069 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL31133533 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL5070768 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL3406205 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL40651 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL1649712 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL34339 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL13785162 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577246-A1 | DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-120117644-A | Zinc oxide particles, photostable UV filters, and methods of use thereof | 纳米技术有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119744162-A | Polyester film-forming polymers for alcohol-based sunscreen formulations | 诺力昂化学品国际有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-12234216-B2 | Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2024044760-A9 | DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240418723-A1 | SEQUENTIAL TREATMENTS AND BIOMARKERS TO REVERSE RESISTANCE TO KINASE INHIBITORS | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2024-12-19 | — | — | US | disclosed |
| US-20240368168-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | ARTIVILA BIOPHARMA (CN) | 2024-11-07 | — | — | US | disclosed |
| US-20240294488-A1 | ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | disclosed |
| US-11292760-B2 | Therapeutic acrylates as enhanced medical adhesives | CARNEGIE MELLON UNIVERSITY (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20210393645-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2021-12-23 | — | — | US | disclosed |
| US-20200255527-A1 | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | PRESIDENT & FELLOWS OF HARVARD COLLEGE | 2020-08-13 | — | — | US | disclosed |
| US-20190262353-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2019-08-29 | — | — | US | disclosed |
| US-8703764-B2 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE JAMES (CA) | 2014-04-22 | — | — | US | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| US-20060287299-A1 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE J | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | IAPP, ALPG, AMY2A | MAOB 2485/4885MAOA 4024/4885KDM4E 4476/4885 |
| US-12234216-B2 | Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof | PYGB, NR3C2, CYP11B1 | MAOB 646/4885MAOA 919/4885KDM4E 397/4885 |
| US-11292760-B2 | Therapeutic acrylates as enhanced medical adhesives | ILK, COL2A1, BMP2 | MAOB 4354/4885MAOA 4214/4885KDM4E 1031/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | MAOB 1322/4885MAOA 1518/4885KDM4E 2426/4885 |
| US-20200255527-A1 | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | KDM1B, KDM2A, KDM3B | MAOB 960/4885MAOA 1195/4885KDM4E 24/4885 |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | MAOB 94/4885MAOA 55/4885KDM4E 1420/4885 |
| US-20240294488-A1 | ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF | CYP11B1, PYGB, CYP11B2 | MAOB 498/4885MAOA 720/4885KDM4E 669/4885 |
| US-20240368168-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | SARM1, BACE1, SARNP | MAOB 259/4885MAOA 110/4885KDM4E 2779/4885 |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | MAOB 81/4885MAOA 183/4885KDM4E 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.